Genmab — September 2015
-
Our key takeaways include: 1) Johnson & Johnson does plan to put its sizeable balance sheet to work for M&A and would leverage its borrowing capacity for the right deal at the right value; 2) Johnson & Johnson aims to grow each business segment organically faster than the market in which it competes; 3) there is a clear strategy to leverage scale and innovation to grow in targeted medical device segments; 4) management believes that biosimilar risk is weighing too much on investor sentiment; 5)
-
-
Patience is a virtue -- we continue to see the potential for Johnson & Johnson to do a large deal. With $34 billion in cash, significant borrowing capacity and Synthes integration now completed, we believe that Johnson & Johnson is moving closer to do larger M&A deals.
-
Tak Budweis.
-
Dara har det alle går efter. Super effektiv og super bivirkningsprofil. Forsøgene udvides til det dobbelte næste år i nye indikationer. Hvis prekliniske data støtter formodningen om effekt i andre indikationer så er der god sikkerhed/sandsynlighed for, at der pgså skal sættes værdi på disse indikationer. Duobodies vil også repræsentere en ikke uvæsenlig værdi. Janssens har nu 11 duobodies i gang. Vi har ingen melding på at et eneste af disse er droppet. Nvovartis har investeret store summer ...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind